Arrowhead Pharmaceuticals vs Monopar Therapeutics
ARWR and MNPR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and MNPR compare
Arrowhead Pharmaceuticals is the larger company, worth 13 times as much as Monopar Therapeutics ($6.2B against $483M).
Monopar Therapeutics scores higher on the StockData Score (7 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | MNPR |
|---|---|---|
| Size and price | ||
| Market cap | $6.2B | $483M |
| Share price | $44.21 | $71.97 |
| Change, 1 year | 7.5% | −17.3% |
| Change, 5 years | −38.6% | 197% |
| Beta (5Y) | 1.53 | 0.66 |
| Employees | 711 | 22 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.3× | – |
| P/B | 13.4× | 3.7× (better) |
| FCF yield | −1.2% | – |
| Fair value | $32.18 | – |
| Margin of safety | −37.4% | – |
| Growth | ||
| Revenue growth (TTM) | 16.8% | – |
| Revenue growth, 5Y average | 56.6% | – |
| Profitability | ||
| Operating margin | −33.8% | – |
| Net margin | −47.8% | – |
| FCF margin | −11.2% | – |
| Return on equity | −64.8% | −19.5% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −2.4× | – |
| Current ratio | 5.90 | 33.56 (better) |
| Altman Z-score | 1.75 | 69.88 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.6% | 92.7% |
| Held by insiders | 4.0% | – |
| Insider net buying, 12 months | −$36.9M | −$5.6M (better) |
| Short interest, % of float | 8.5% | – |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- MNPR stock overview
- MNPR income statement
- MNPR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.